YorkBridge Wealth Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

YorkBridge Wealth Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-457	Closed	-$27K	–	836
2018 Q2	$27K	Sell	457 -67	-13%	-$3.47K	0.01%	454
2018 Q1	$24K	Buy	524 +71	+16%	+$2.96K	0.01%	481
2017 Q4	$17K	Sell	453 -152	-25%	-$6.01K	0.01%	562
2017 Q3	$24K	Buy	605 +3	+0.5%	+$130	0.01%	478
2017 Q2	$26K	Hold	602	–	–	0.01%	454
2017 Q1	$20K	Buy	602 +196	+48%	+$5.25K	0.01%	512
2016 Q4	$9K	Buy	+406	New	+$9.07K	0.01%	617

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

YorkBridge Wealth Partners's SUPN Position: Q3 2018 in Review

YorkBridge Wealth Partners sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 457 shares — an estimated $27K sold.

YorkBridge Wealth Partners first reported a position in SUPN in Q4 2016 and held it in 7 quarters. The position peaked at $27K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

YorkBridge Wealth Partners reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
YorkBridge Wealth Partners sold 457 Supernus Pharmaceuticals shares in Q3 2018, an estimated $27K.
YorkBridge Wealth Partners first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 7 quarters.
YorkBridge Wealth Partners's Supernus Pharmaceuticals position peaked at $27K in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.